Getting your patients started
with NUEDEXTA®

Specific Populations1

No dose adjustments are required in patients with mild-to-moderate renal or hepatic impairment. NUEDEXTA has not been evaluated in patients with severe renal or hepatic impairment

Recommended dosage and administration

  • Starting dose: One capsule daily by mouth for 7 days
  • Maintenance dose: After 7 days, 1 capsule every 12 hours

Titrate from QD to Q12H on Day 81

Days 1-7

1 capsule QD

DMQ20-10
Beginning Day 8

1 capsule Q12H

DMQ20-10DMQ20-10

Recommended maintenance dose

Dosing instructions1

Instruct patients to not take more than 2 capsules in a 24-hour period and to make sure that there is an approximate 12-hour interval between doses

If a dose is missed, instruct patients to not take a double dose

The need for continued treatment should be reassessed periodically, as spontaneous improvement of PBA symptoms occurs in some patients

Document your diagnosis of PBA using ICD-10 code F48.2a,2

  • NUEDEXTA is categorized in the "Central Nervous System, Other" pharmacologic class in the USP model formulary2,3
Recommended prescription for Nuedexta therapy

Script pad is for illustration purposes only and represents prescription for maintenance therapy after initial-week titration period with QD dosing.

 

aIntended for reference only. ICD-10-CM codes submitted to the payer must be determined by the provider/physician and accurately describe PBA as the diagnosis for which the patient receives NUEDEXTA treatment.